Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

New York, USA, April 14, 2025 (GLOBE NEWSWIRE) -- Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight The psoriasis pipeline possesses some drugs in ...

While certain skin conditions such as acne can seem easy to diagnose from home, others can be a bit trickier, like eczema and ...

The IL-23 pathway is already targeted by various injectable antibody-based drugs, including AbbVie's own Skyrizi (risankizumab) – which is FDA-approved for plaque psoriasis, psoriatic arthritis ...

Results from the SCULPTURE patient-reported outcomes study showed that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx reported no impact of skin disease on their ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin. Johnson & Johnson has shared positive data from a subgroup analysis of ...

Skin tone can play a role in the intensity and length of hyperpigmentation treatments. As noted by Dr. Cynthia Cobb, DNP, APRN, WHNP-BC, MEP-C, people with fair, medium, and dark skin tones can ...